Ortega-Deballon, P. http://orcid.org/0000-0001-7874-7743
Renard, Y. http://orcid.org/0000-0001-6036-0006
de Launay, J.
Lafon, T.
Roset, Q.
Passot, G.
Funding for this research was provided by:
Becton, Dickinson and Company
Article History
Received: 23 January 2023
Accepted: 10 June 2023
First Online: 27 June 2023
Declarations
:
: POD declares paid participations to conferences and consultancy fees from BARD-BD, Covidien-Medtronic, LifeCell-Acelity, Cousin and Nestlé nutrition. YR declares consultancy fees from Becton, Dickinson and Company, Medtronic, and Hartmann. JdL works for Becton, Dickinson and Company. TL and QR both work for Heva. GP declares speaker fees from Becton, Dickinson and Company.
: This study respected human rights, complied with regulations in force and patient consent was not necessary because it uses pseudonymised secondary data and the protection of patients’ rights and freedom were guaranteed. In France, all patients are informed of the implementation of the SNDS and the possible re-use of their personal health data in accordance with the procedures defined by Article R.1461-9 of the Public Health Code. Access to the data fell under the 006 framework (MR-006) developed by the French data protection authority (Commission Nationale de l’Informatique et des Libertés, CNIL). The study was registered at the Health Data Hub on 21/04/2021 (Declaration of conformity No. 2214421v0 of 17/07/2019).